Abstract:The objective of the research was to improve the process design of a combined antisolvent-cooling crystallization to reduce the degree of agglomeration of a real active pharmaceutical ingredient product, which was manufactured using a crystallization stage employing a methanol/water solvent system. Knowledge was gained from the use of process analytical technology (PAT) tools to monitor the process variables, allowing particle size, degree of agglomeration, solute concentration, and supersaturation to be tracked throughout the process. Based on knowledge of the solubility behavior and interpretation of the PAT histories, changes were made to the sequences of antisolvent addition and cooling within the crystallization process to reduce agglomeration in the final product. Different seed loadings and seeding addition points were also investigated to maintain operation within lower supersaturation regions of the phase diagram to limit agglomeration and avoid an undesired polymorphic transformation to an unstable form. The improved sequences of operations and seeding conditions did not provide sufficient improvement in the product quality and so were augmented by applying wet milling for further deagglomeration followed by temperature cycling to remove fine particles generated during milling. Open-loop heating and cooling cycles produced some limited improvements, whereas closed-loop direct nucleation control methods using FBRM as a feedback sensor for particle counts per second were much more successful at producing high-quality crystals of the desired polymorphic form. The work shows that understanding the trajectory of the process through the phase diagram to follow appropriate supersaturation profiles gives improved control of the various kinetic mechanisms and can be used to improve the quality of the final product.

Step‐By‐Step Standardization of the Bottom‐Up Semi‐Automated Nanocrystallization of Pharmaceuticals: A Quality By Design and Design of Experiments Joint Approach (Small 25/2024)

Top-down method for lab-scale production of nanocrystals of active molecules: Formulation approach and selection of optimal process parameters

Solid formulations by a nanocrystal approach: critical process parameters regarding scale-ability of nanocrystals for tableting applications

A Comprehensive Workflow towards More Equant‐Shaped Crystals of Active Pharmaceutical Ingredients

Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches

Pharmaceutical Digital Design: From Chemical Structure through Crystal Polymorph to Conceptual Crystallization Process

Design of Experiments-Driven Optimization of Spray Drying for Amorphous Clotrimazole Nanosuspension

Surfactant-Polymer Complexation and Competition on Drug Nanocrystal Surfaces Control Crystallinity

The Evolution of Nanocrystalline Drug Delivery System

Use of Wet Milling Combined with Temperature Cycling to Minimize Crystal Agglomeration in a Sequential Antisolvent-Cooling Crystallization

Quality-by-Design Approach to Process Intensification of Bioinspired Silica Synthesis

Polymorph selection of pharmaceutical cocrystals via bench-top and continuous production techniques

Automated Continuous Crystallization Platform with Real-Time Particle Size Analysis via Laser Diffraction

Modular microfluidic platform for solubility measurement, nucleation statistics and polymorph screening of active pharmaceutical ingredients: Irbesartan, Rimonabant, Aripiprazole and Sulfathiazole

Pharmaceutical Cocrystals: A Perspective on Development and Scale-up of Solution Cocrystallization

Strategizing Spray Drying Process Optimization for the Manufacture of Redispersible Indomethacin Nanoparticles Using Quality-by-Design Principles

Production of Pure Drug Nanocrystals and Nano Co-Crystals by Confinement Methods.

Process development in Quality‐by‐Design paradigm for anti‐solvent aided crystallization: impact of crystallization parameters on particle morphology and dissolution behaviour of Dexlansoprazole active pharmaceutical ingredient

Designing Continuous Crystallization Protocols for Curcumin Using PAT Obtained Batch Kinetics

Crystallization Methods for Preparation of Nanocrystals for Drug Delivery System

Crystal Engineering in the design of New Solid Pharmaceutical Forms with enhanced pharmaceutical properties